Although the results of a double-blind, randomized, placebo-controlled clinical trial of adding uric acid to thrombolytic therapy hinted at potentially beneficial effects on acute ischemic stroke outcomes, Dr. Steven M. Greenberg of Harvard Medical School, Boston, advised waiting for the results of larger trials that confirm the potential benefits given the poor history behind seemingly promising preclinical therapies for acute stroke.